Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Holodniy, Mark ^a,b   Brown, Sheldon T ^c,d   Cameron, D William ^e,f   Kyriakides, Tassos C ^g   Angus, Brian ^h   Babiker, Abdel ⁱ   Singer, Joel ^f   Owens, Douglas K ^a,b   Anis, Aslam ^f   Goodall, Ruth ⁱ   Hudson, Fleur ⁱ   Piaseczny, Mirek ^f   Russo, John ^g   Schechter, Martin ^f   Deyton, Lawrence ^j,k   Darbyshire, Janet ⁱ  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f ST PAUL S HOSPITAL   (Canada)

^g VA Cooperative Studies Program Coordinating Center   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ MRC CLINICAL TRIALS UNIT   (United Kingdom)

^j DEPARTMENT OF VETERANS AFFAIRS   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTIDRUG RESISTANCE;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 79953329405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014764     Document Type: Article

References (31)

1. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, et al. (2005) The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 165: 416-423.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
3. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, et al. (2002) Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 18: 835-838.
4. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353: 863-868.
5. Miller V, Larder BA, (2001) Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 6 (Suppl 3): 25-44.
6. Race E, Dam E, Obry V, Paulous S, Clavel F, (1999) Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. Aids 13: 2061-2068.
7. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, et al. (2008) The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 13: 625-639.
8. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, et al. (2005) Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. Aids 19: 1081-1089.
9. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, et al. (2008) Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 22: 2187-2198.
10. Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, et al. (2000) HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 5: 49-55.
11. Montaner JS, Harrigan PR, Jahnke N, Raboud J, Castillo E, et al. (2001) Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. Aids 15: 61-69.
12. Rottmann C, Miller V, Staszewski S, (1999) Mega-HAART: preliminary results and correlation with baseline resistance. Antivir Ther 4 (Suppl 3): 93-94.
13. Pai NP, Lawrence J, Reingold AL, Tulsky JP, (2006) Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev 3: CD006148.
14. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, et al. (2004) Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18: 217-226.
15. Lawrence J, Hullsiek KH, Thackeray LM, Abrams DI, Crane LR, et al. (2006) Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr 43: 169-178.
16. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, et al. (2003) Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349: 837-846.
17. Panel on Antiretroviral Guidelines for Adult and A Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
18. Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, et al. (2008) Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 80: 565-576.
19. Anis AH, Noysk B, Sun H, Guh DP, Bansback N, Li X, et al. (2009) Quality of Life of patients with Advanced HIV/AIDS: Measuring the Impact of both AIDS Defining Events and Non-AIDS Serious Adverse Events. J Acquir Immune Defic Syndr 51: 631-639.
20. Lo Re V 3rd, Kostman JR, Amorosa VK, (2008) Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 12: 587-609, ix.
21. Kauf TL, Roskell N, Shearer A, Gazzard B, Mauskopf J, et al. (2008) A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy. Value Health.
22. Bonnet F, Chene G, Thiebaut R, Dupon M, Lawson-Ayayi S, et al. (2007) Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 8: 547-554.
23. Morse CG, Kovacs JA, (2006) Metabolic and skeletal complications of HIV infection: the price of success. JAMA 296: 844-854.
24. Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, et al. (2003) An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials 24 (4): 481-500.
25. (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41: 1-19.
26. Lawrence J KH, Coakley E, Bates M, Weidler J, Lie Y, et al. (2006) Antiretroviral Phenotypic Susceptibility Score as a Predictor of Treatment Response in Persons with Multi-drug-resistant HIV-1. Available:http://www.aegis.org/conferences/croi/2006/651b.pdf.
27. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, et al. (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12: 255-266.
28. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, et al. (2009) Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr 50: 27-36.
29. Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, et al. (2003) An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials 24: 481-500.
30. Hughes A, Barber T, Nelson M, (2008) New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 57: 1-10.
31. Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, et al. (2010) A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One 5: e10307.